PATENT CLAIM ANALYSIS

Application Number: 16186879
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["514", "001400"]

Abstract:
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.

Claim (Index 48):
A method of treating a disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to  claim 45 , wherein said disease or condition is selected from the group consisting of\n an acute or chronic inflammatory disease or medical condition, general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock; an autoimmune disease or medical condition, rheumatoid arthritis, gouty arthritis and multiple sclerosis; a metabolic disease or medical condition accompanied by weight gain, obesity, feeding disorders and Prader-Willi Syndrome; a metabolic disease or medical condition accompanied by weight loss, anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly; a neoplastic disease or medical condition, skin cancer and cancer cachexia; a reproductive or sexual medical condition, endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females; a disease or medical condition resulting from treatment or insult to an organism, organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis; a cardiovascular disease or medical condition, hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia; a pulmonary disease or medical condition, acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma; enhanced immune tolerance; allergies; a dermatological disease or medical condition, psoriasis, skin pigmentation depletion, acne and keloid formation; a behavioral or central nervous system or neuronal disease or medical condition, anxiety, depression, memory dysfunction and neuropathic pain; and a renal disease or medical condition, renal cachexia and natriuresis.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.46875
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12602010', '14024961', '13074565', '11988468', '15055873']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.9005790138029127
- 35 USC 102 Novelty (BERT): 0.6132141660509675
- Combined Prediction Score: 0.8718425290277182
- Mean Citation Score: 625.486862
- Max Citation Score: 672.6033
- Similarity Product: 479.16861735515

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test